SS-31 Peptide (Elamipretide): Complete Research Guide
The SS-31 peptide (elamipretide) is a synthetic, cell-permeable tetrapeptide structurally engineered to target and accumulate within the inner mitochondrial membrane. Unlike traditional peptides that bind to cell-surface receptors, SS-31 directly interacts with cardiolipin, a structurally unique phospholipid that maintains cristae architecture. By stabilizing this membrane environment, SS-31 optimizes electron transport chain function and reduces reactive oxygen species generation, making it a primary focus in in-vitro models of mitochondrial dysfunction.
What is the SS-31 Peptide (Elamipretide)?
The SS-31 peptide (elamipretide) is a synthetic, cell-permeable tetrapeptide belonging to the Szeto-Schiller (SS) class of aromatic-cationic compounds. Structurally characterized by an alternating sequence of basic and aromatic amino acids, SS-31 selectively targets and accumulates within the inner mitochondrial membrane (IMM). In preclinical research, SS-31 is primarily investigated for its unique capacity to bind cardiolipin, thereby stabilizing mitochondrial cristae and optimizing electron transport chain function without acting as a traditional biochemical free radical scavenger.
Physicochemical Specifications
SS-31 relies on a highly conserved sequence framework that dictates its physicochemical properties and cellular penetration kinetics. The alternating aromatic-cationic motif yields a net positive charge under physiological conditions, facilitating electrophoretic accumulation across the highly negative mitochondrial membrane potential observed in in-vitro models.
| Specification | Data |
|---|---|
| Amino Acid Sequence | D-Arg-Dmt-Lys-Phe-NH2 |
| Molecular Formula | C32H49N9O5 |
| Molar Mass | 639.8 g/mol |
| Net Charge (pH 7.4) | +3 |
Structural Components and Proteolytic Resistance
Unlike endogenous peptides, SS-31 incorporates modified and D-isomer amino acids. These synthetic alterations are heavily investigated in the literature for their role in conferring resistance to aminopeptidase degradation, ensuring structural stability during cellular assays and preclinical pharmacokinetic modeling.
| Residue | Chemical Role in Motif | Functional Contribution in Models |
|---|---|---|
| D-Arginine (D-Arg) | Cationic / D-isomer | Provides a positive charge; resists enzymatic cleavage in serum. |
| 2,6-dimethyltyrosine (Dmt) | Aromatic / Modified | Enhances lipophilicity; drives hydrophobic interaction with cardiolipin. |
| Lysine (Lys) | Cationic | Contributes to the overall +3 net charge required for IMM targeting. |
| Phenylalanine (Phe) | Aromatic | Maintains the alternating spatial arrangement of the tetrapeptide. |
Nomenclature and Research Designations
In scientific literature and biochemical databases, SS-31 appears under multiple designations depending on the developmental stage of the research or the specific laboratory initiating the study. Researchers tracking historical data or querying literature databases such as PubMed will encounter several synonymous identifiers.
| Nomenclature Type | Identifier |
|---|---|
| Primary Chemical Designation | SS-31 (Szeto-Schiller 31) |
| United States Adopted Name (USAN) | Elamipretide |
| Preclinical Investigational Codes | MTP-131, Bendavia |
The core mechanism defining SS-31 in laboratory models is its non-reliance on specific protein receptors. Instead, the peptide engages in direct electrostatic and hydrophobic interactions with cardiolipin, an anionic phospholipid exclusive to the IMM. This interaction is documented in structural biology studies to influence the biophysical properties of the membrane, altering the curvature and physical stability of the cristae where oxidative phosphorylation occurs. Ongoing inquiries into these mechanisms, including phase-specific study designs, can be found by reviewing targeted queries on ClinicalTrials.gov and corresponding preclinical publications.
The Szeto-Schiller Aromatic-Cationic Structural Motif
The SS-31 peptide (elamipretide) is defined by its distinctive aromatic-cationic sequence, specifically characterized as D-Arg-Dmt-Lys-Phe-NH2. This alternating arrangement of basic and aromatic amino acids generates a highly cell-permeable structural motif that facilitates rapid cellular entry without relying on active transport mechanisms or specific receptors. The strategic inclusion of a D-amino acid and the synthetic derivative 2,6-dimethyltyrosine (Dmt) ensures high resistance to proteolytic degradation in experimental biological models.
Alternating Residues and Membrane Permeability
The core innovation of the Szeto-Schiller motif lies in its precisely arranged sequence. The basic amino acids (Arginine and Lysine) carry positive charges at physiological pH, while the aromatic residues (Dmt and Phenylalanine) provide necessary lipophilicity. This sequence creates an amphipathic-like dynamic, though structurally distinct from traditional amphipathic helices.
In laboratory assays, this specific alternating structural design enables concentration-independent passive diffusion across plasma membranes. The positive charges initially interact with anionic phospholipid headgroups, while the bulky, hydrophobic aromatic rings intercalate into the lipid bilayer, facilitating rapid translocation.
| Position | Residue | Chemical Classification | Primary Structural Role |
|---|---|---|---|
| 1 (N-terminus) | D-Arginine (D-Arg) | Basic / Cationic (D-isomer) | Provides positive charge; prevents aminopeptidase cleavage. |
| 2 | 2,6-Dimethyltyrosine (Dmt) | Aromatic / Synthetic | Confers lipophilicity; supplies electron-dense phenolic ring. |
| 3 | Lysine (Lys) | Basic / Cationic | Provides secondary positive charge for electrostatic targeting. |
| 4 (C-terminus) | Phenylalanine (Phe-NH2) | Aromatic / Amidated | Enhances hydrophobicity; amidation eliminates negative charge. |
Synthetic Modifications: Dmt and Proteolytic Resistance
Standard peptide sequences undergo rapid enzymatic breakdown when introduced to culture media or biological fluids. Researchers investigating SS-31 peptide properties observe significantly extended half-lives due to two deliberate synthetic modifications. First, the N-terminal Arginine is synthesized as a right-handed (D-) stereoisomer, which effectively blocks degradation by exopeptidases.
Second, the substitution of standard tyrosine with 2,6-dimethyltyrosine (Dmt) introduces significant steric hindrance. The two methyl groups on the phenolic ring protect the adjacent peptide bonds from endopeptidase cleavage. Literature accessible via PubMed searches on Szeto-Schiller modifications indicates that Dmt not only shields the backbone but also enhances the electron-scavenging capacity evaluated in isolated mitochondrial studies.
| Modification | Standard Amino Acid Equivalent | Impact on In-Vitro Stability |
|---|---|---|
| D-Isomer Incorporation | L-Arginine | Confers nearly complete resistance to N-terminal aminopeptidases. |
| 2,6-Dimethylation | L-Tyrosine | Steric hindrance blocks endopeptidase activity at the 1-2 peptide bond. |
| C-Terminal Amidation | Free Carboxyl Terminus | Prevents carboxypeptidase degradation and stabilizes net positive charge. |
Physicochemical Profile of the SS-31 Motif
The combination of these structural elements results in a highly specific physicochemical profile. The C-terminal amidation removes the standard negative charge associated with a free carboxyl group, leaving the molecule with a net charge of +3 at pH 7.4. This localized cationic density is the primary driver for its accumulation in highly electronegative subcellular compartments, functioning independently of the transmembrane potential.
| Physicochemical Property | Value / Characteristic | Relevance in Experimental Models |
|---|---|---|
| Net Charge (pH 7.4) | +3 | Drives electrostatic attraction to anionic cardiolipin domains. |
| Molecular Weight | 639.8 g/mol | Small molecular size facilitates rapid aqueous diffusion. |
| Solubility | Highly water-soluble | Allows straightforward reconstitution for cell culture applications. |
Mechanism of Action: Direct Cardiolipin Binding
The SS-31 peptide exerts its primary cellular effects through direct, receptor-independent binding to cardiolipin, a unique anionic phospholipid residing almost exclusively within the inner mitochondrial membrane (IMM). This interaction relies on a precise combination of electrostatic attraction and hydrophobic insertion, anchoring the peptide directly to the membrane interface. By physically associating with cardiolipin, SS-31 alters the phospholipid’s structural conformation, a mechanism observed in preclinical models to be critical for preserving mitochondrial bioenergetics.
Electrostatic and Hydrophobic Interaction Dynamics
The binding affinity of SS-31 to the IMM is governed by its specific sequence of alternating aromatic and cationic residues. Cardiolipin possesses a unique dimeric structure featuring two negatively charged phosphate headgroups and four hydrophobic acyl chains. The cationic residues in SS-31 initiate the interaction via strong electrostatic attraction to the phosphate headgroups. Following this initial electrostatic localization, the aromatic residues penetrate the shallow hydrophobic core of the lipid bilayer, interacting directly with cardiolipin’s acyl chains.
| SS-31 Amino Acid Residue | Chemical Property | Cardiolipin Interaction Target | Binding Mechanism |
|---|---|---|---|
| D-Arginine (D-Arg) | Cationic (Basic) | Phosphate Headgroup | Electrostatic attraction |
| 2,6-dimethyltyrosine (Dmt) | Aromatic / Hydrophobic | Acyl Chains | Hydrophobic insertion / Pi-stacking |
| Lysine (Lys) | Cationic (Basic) | Phosphate Headgroup | Electrostatic attraction |
| Phenylalanine (Phe) | Aromatic / Hydrophobic | Acyl Chains | Hydrophobic insertion |
Receptor-Independent Inner Mitochondrial Membrane Localization
Unlike conventional peptide compounds that initiate intracellular signaling cascades via cell-surface G-protein coupled receptors (GPCRs), the SS-31 peptide operates entirely independent of surface proteins. Literature indicates the peptide exhibits high aqueous solubility while retaining sufficient lipophilicity to passively cross the plasma membrane and the outer mitochondrial membrane (OMM). Intracellular accumulation is driven by the thermodynamic favorability of the SS-31-cardiolipin complex at the IMM, effectively bypassing classical signal transduction pathways. For broader literature on mitochondrial targeting mechanisms, researchers can review published structural studies.
| Property | SS-31 Peptide (Elamipretide) | Classical Peptide Hormones |
|---|---|---|
| Target Location | Inner Mitochondrial Membrane (IMM) | Plasma Membrane (Extracellular) |
| Binding Target | Cardiolipin (Phospholipid) | Protein Receptors (e.g., GPCRs) |
| Cellular Penetration | Passive diffusion (highly permeable) | Requires active transport or fails to penetrate |
| Signaling Pathway | Direct structural membrane stabilization | Secondary messenger cascades (cAMP, IP3) |
Structural Modification of the Cardiolipin Microenvironment
Preclinical in vitro studies demonstrate that the physical binding of SS-31 to cardiolipin alters the local microenvironment of the IMM. Under physiological stress, cardiolipin typically undergoes pathological remodeling or peroxidation, which disrupts its natural association with cytochrome c. When SS-31 binds cardiolipin, it sterically protects the phospholipid and stabilizes its electrostatic interaction with cytochrome c. This structural preservation prevents cytochrome c from exposing its heme group to act as a peroxidase, maintaining its primary function as an electron carrier, as detailed in in vitro mitochondrial research.
| Mitochondrial Component | Unbound State (Stress Model) | SS-31 Bound State (In Vitro Observation) |
|---|---|---|
| Cardiolipin Structure | Susceptible to acyl chain peroxidation | Sterically shielded from oxidative degradation |
| Cytochrome c Function | Acts as a peroxidase; generates ROS | Functions strictly as an electron carrier |
| Membrane Integrity | Loss of IMM cristae curvature | Maintained cristae folding and tight junctions |
Stabilization of Inner Mitochondrial Membrane Cristae
The SS-31 peptide stabilizes the physical curvature of inner mitochondrial membrane (IMM) cristae through direct electrostatic and hydrophobic interactions with cardiolipin. By securing the cardiolipin-cytochrome c complex in laboratory models, the peptide preserves cristae architecture and prevents cytochrome c from shifting into a pathological peroxidase state during oxidative stress. Preclinical investigations suggest this structural preservation is fundamental to maintaining mitochondrial bioenergetics.
Cardiolipin is a unique, cone-shaped phospholipid exclusive to the IMM, dictating the tight folds and extreme curvature of mitochondrial cristae. Under conditions of oxidative stress, cardiolipin undergoes rapid peroxidation. This chemical alteration compromises its conical geometry, leading to the flattening of cristae folds, membrane depolarization, and impaired electron transport. Laboratory analyses demonstrate that SS-31 selectively partitions into the IMM, binding to cardiolipin to reinforce its structural integrity and maintain the necessary membrane curvature.
| Membrane Component | Standard Physiological Role | Interaction with SS-31 Peptide |
|---|---|---|
| Cardiolipin (CL) | Maintains IMM curvature; anchors electron transport chain complexes. | Forms stable complex via electrostatic/hydrophobic bonds, shielding CL from oxidation. |
| Cytochrome c | Transfers electrons between Complex III and Complex IV. | SS-31 prevents pathological unfolding and tight binding to peroxidized CL. |
| ATP Synthase (Complex V) | Generates ATP at cristae apices. | Function supported indirectly via maintenance of cristae morphology and proton gradient. |
A critical secondary mechanism of SS-31 involves the regulation of cytochrome c activity. In a homeostatic environment, cytochrome c acts as a mobile electron carrier. However, when exposed to reactive oxygen species (ROS), cytochrome c binds tightly to oxidized cardiolipin, unfolding its tertiary structure. This conformational change transforms cytochrome c into a peroxidase, which accelerates cardiolipin degradation and initiates apoptotic cascades. Research literature indicates that the SS-31 peptide competitively interacts with cardiolipin, inhibiting the cytochrome c peroxidase transition. For further mechanistic studies on this interaction, researchers often query cytochrome c peroxidase inhibition by SS-31.
| Cytochrome c State | Catalytic Function | Mitochondrial Consequence |
|---|---|---|
| Native (Electron Carrier) | Transfers electrons (Complex III to IV) | Maintains oxidative phosphorylation and ATP synthesis. |
| Unfolded (Peroxidase) | Catalyzes H2O2-dependent CL oxidation | Destroys IMM curvature; triggers membrane permeabilization. |
| SS-31 Stabilized | Restored electron transfer | Prevents peroxidase conversion; preserves CL architecture. |
Electron microscopy studies in preclinical models of ischemia-reperfusion frequently utilize specific morphological markers to quantify the protective effects of SS-31 on cristae architecture. The preservation of these microstructures correlates directly with reduced mitochondrial swelling and maintained electron transport chain efficiency during severe cellular stress.
| Morphological Marker | Pathological State (Oxidative Stress) | Observation in SS-31 Preclinical Models |
|---|---|---|
| Cristae Density | Significantly reduced; vast matrix spaces. | Maintained density comparable to non-stressed controls. |
| Membrane Curvature | Flattened or tubular cristae structures. | Preserved acute apical curvature and tight junctions. |
| Organelle Volume | Severe mitochondrial swelling (megamitochondria). | Standard organelle volume; prevention of matrix expansion. |
Electron Transport Chain Efficiency and Oxidative Stress
The SS-31 peptide preserves electron transport chain (ETC) efficiency by maintaining the spatial organization of mitochondrial supercomplexes along the inner mitochondrial membrane. By anchoring cardiolipin and stabilizing cristae architecture, the peptide minimizes the physical distance between ETC complexes, optimizing ATP synthesis. This structural preservation directly limits aberrant electron leakage, preventing the premature generation of reactive oxygen species (ROS) at the source rather than acting as a traditional post-generation free-radical scavenger.
Supercomplex Assembly and ATP Synthesis Optimization
In functional cellular models, the ETC operates via closely associated multimeric structures called respirasomes. Cardiolipin acts as the essential lipid scaffold organizing Complexes I, III, and IV into these assemblies. In-vitro research demonstrates that cardiolipin degradation causes respirasomes to disassemble, increasing the distance electrons must traverse. By binding cardiolipin, the SS-31 peptide preserves this tight macromolecular architecture. Electron transfer rates remain optimal under these conditions, sustaining the proton-motive force required to drive ATP synthase (Complex V) activity.
| ETC Component | Role in Oxidative Phosphorylation | Cardiolipin Dependence (Target for SS-31) |
|---|---|---|
| Complex I (NADH:ubiquinone oxidoreductase) | Initiates electron transfer and pumps protons across the membrane. | High; requires cardiolipin for supercomplex integration and stability. |
| Complex III (Cytochrome bc1 complex) | Transfers electrons from ubiquinol to cytochrome c. | Critical; cardiolipin mediates dimerization and structural integrity. |
| Complex IV (Cytochrome c oxidase) | Final electron acceptor; reduces oxygen to water. | Absolute; structurally binds tightly to multiple cardiolipin molecules. |
| Complex V (ATP Synthase) | Utilizes the proton gradient to synthesize ATP. | High; cardiolipin shapes cristae curvature to optimize ATP synthesis. |
Mitigation of Electron Leakage
Disorganized ETC complexes cause electron flow to stall, significantly increasing the probability of single electrons escaping the transport pathway. These rogue electrons react prematurely with molecular oxygen to form highly reactive superoxide anions (O2•−). Preclinical assays indicate that by restoring cardiolipin-protein interactions, elamipretide ensures electrons remain confined to their designated redox pathways. This mechanism drastically reduces endogenous ROS generation in laboratory models of metabolic stress.
| Site of Electron Leakage | Mechanism of ROS Generation | Observed Impact of SS-31 Peptide in Models |
|---|---|---|
| Complex I (Flavin mononucleotide site) | Reverse electron transport (RET) during high proton-motive force. | Stabilizes complex architecture, reducing RET-induced superoxide formation. |
| Complex III (Qo site) | Bifurcated electron transfer stalling due to structural dissociation. | Maintains ubiquinol binding pocket integrity, limiting Q-semiquinone radical accumulation. |
Structural Versus Scavenging Antioxidant Mechanisms
Unlike conventional antioxidants that neutralize free radicals after formation, the SS-31 peptide functions upstream of oxidative damage. Researchers investigating mitochondrial dysfunction classify elamipretide as a structural protectant. By preventing the membrane collapse that triggers ROS cascades, the peptide preserves cellular redox homeostasis without interfering with physiological, low-level ROS signaling required for normal cellular function.
| Mechanism Parameter | Traditional Antioxidants (e.g., Alpha-Tocopherol) | SS-31 Peptide (Elamipretide) |
|---|---|---|
| Primary Action | Chemical reduction of existing free radicals. | Structural preservation of the inner mitochondrial membrane. |
| Site of Action | Cytosol and broad lipid bilayers. | Highly specific to mitochondrial cardiolipin domains. |
| Impact on ETC Architecture | None; does not organize supercomplexes. | Maintains tight respirasome packing and complex proximity. |
| Effect on ATP Synthesis | Indirect or negligible. | Direct optimization via restored proton gradient efficiency. |
Observations detailing the relationship between cristae topology and ROS suppression are extensively documented in biochemical literature. Researchers seeking current in-vitro data on these structural dynamics can consult the PubMed database for elamipretide and the electron transport chain or review specific assays detailing the SS-31 peptide and reactive oxygen species generation.
Mitochondrial Accumulation Kinetics and Cellular Penetration
The SS-31 peptide rapidly diffuses across cellular membranes to concentrate specifically at the inner mitochondrial membrane (IMM). Preclinical pharmacokinetic models indicate that SS-31 achieves IMM concentrations up to 5,000 times higher than extracellular levels through direct binding affinity with cardiolipin. Crucially, this robust subcellular accumulation is entirely independent of the mitochondrial membrane potential (ΔΨm), allowing consistent targeted delivery even in severely damaged or depolarized mitochondria.
Membrane Potential Independence Versus TPP-Targeted Molecules
A primary challenge in targeted mitochondrial research is delivering compounds into organelles experiencing oxidative stress or ischemic damage. Conventional mitochondria-targeting moieties, such as triphenylphosphonium (TPP) lipophilic cations, rely on a healthy, hyperpolarized electrochemical gradient (a highly negative interior) to drive matrix accumulation. When mitochondria undergo stress, the IMM rapidly depolarizes. This loss of membrane potential halts the cellular uptake of TPP-conjugated compounds precisely when functional intervention is most investigated in cellular models.
SS-31 circumvents this limitation entirely. Its accumulation is driven not by the electrochemical gradient, but by the thermodynamic favorability of its structural interactions with cardiolipin. As reported in the literature, this unique mechanism ensures the peptide localizes to the IMM even after total mitochondrial depolarization.
| Targeting Mechanism | Primary Driving Force for Accumulation | Dependence on Membrane Potential (ΔΨm) | Accumulation in Depolarized/Damaged Mitochondria |
|---|---|---|---|
| SS-31 (Elamipretide) | Electrostatic and hydrophobic binding to cardiolipin | Independent | Maintained (High) |
| TPP-Conjugated Compounds | Electrochemical gradient (Nernst equation kinetics) | Highly Dependent | Abolished (Low to None) |
Concentration Gradient Kinetics and Subcellular Partitioning
Laboratory investigators procuring research-grade SS-31 peptide frequently analyze its unique concentration kinetics in cellular assays. The molecule does not passively equilibrate across aqueous compartments. Instead, it actively partitions into the IMM lipid bilayer, creating a steep, localized concentration gradient. The binding affinity to cardiolipin acts as an intracellular sink, continually drawing the peptide inward until saturation occurs at the IMM interface.
| Subcellular Compartment | Relative Concentration Ratio (Approximate) | Primary State of Peptide |
|---|---|---|
| Extracellular Medium | 1x (Baseline) | Free in solution |
| Cytosol | 10x – 50x | Transient transit |
| Mitochondrial Matrix | Low (Excluded) | N/A |
| Inner Mitochondrial Membrane (IMM) | 1,000x – 5,000x | Cardiolipin-bound |
Traversing the Plasma and Outer Mitochondrial Membranes
The physical chemistry of the Szeto-Schiller motif facilitates rapid, unassisted cellular entry. Despite carrying a net positive charge (+3 at physiological pH), the alternating aromatic residues in the sequence (D-Arg-Tyr-Lys-Phe-NH2) effectively shield the cationic charges through electron delocalization. This structural characteristic allows the peptide to partition through the hydrophobic core of the lipid bilayer without requiring specific transport proteins, receptors, or endocytosis.
| Biological Barrier | Traversal Mechanism | Rate of Penetration in In-Vitro Models |
|---|---|---|
| Plasma Membrane | Passive lipid bilayer diffusion via aromatic charge shielding | Rapid (< 2 minutes) |
| Outer Mitochondrial Membrane (OMM) | Diffusion through VDACs and lipid domains | Rapid |
| Inner Mitochondrial Membrane (IMM) | Arrested; integration into the cristae structure via cardiolipin | Stable accumulation |
Because the peptide is not sequestered in endosomes, it avoids lysosomal degradation, ensuring a high fraction of the intact molecule reaches the mitochondrial target. This efficient cellular penetration profile makes SS-31 an essential reference compound for researchers designing novel mitochondrially targeted therapeutics, as investigated in models of pharmacokinetic distribution.
Comparative Analysis: SS-31 vs. MOTS-c
The SS-31 peptide (elamipretide) is a synthetic, four-amino-acid Szeto-Schiller compound that physically stabilizes inner mitochondrial membrane cardiolipin, whereas MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDP) that regulates metabolic signaling networks via AMPK activation. Researchers investigating mitochondrial physiology frequently contrast these two molecules because they represent entirely divergent theoretical approaches to mitochondrial modulation: direct biophysical structural preservation versus intracellular metabolic signaling.
Origin and Structural Characteristics
SS-31 relies on an engineered alternating aromatic-cationic motif designed specifically to penetrate cellular membranes independent of active transport mechanisms. In contrast, MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a naturally occurring sequence encoded directly by mitochondrial DNA. While the SS-31 peptide is manufactured via solid-phase peptide synthesis (SPPS) for in-vitro structural investigations, MOTS-c represents an endogenous signaling molecule isolated or synthesized to study systemic metabolic feedback loops.
| Structural Property | SS-31 (Elamipretide) | MOTS-c |
|---|---|---|
| Origin | Synthetic Szeto-Schiller peptide | Mitochondrial-derived peptide (MDP) |
| Sequence Length | 4 amino acids (Tetrapeptide) | 16 amino acids |
| Molecular Weight | ~639 g/mol | ~2174 g/mol |
| Sequence Characteristics | Alternating aromatic-cationic residues | Endogenous linear peptide sequence |
Divergent Mechanisms of Action
The fundamental distinction between SS-31 and MOTS-c lies in their cellular targets. SS-31 acts biophysically rather than enzymatically. It selectively accumulates on the inner mitochondrial membrane (IMM) and binds directly to cardiolipin. This electrostatic and hydrophobic interaction prevents cytochrome c peroxidase activity and maintains cristae architecture under oxidative stress. Literature documented in structural biology models demonstrates this non-receptor-mediated targeting.
MOTS-c functions as a retrograde signaling hormone. Rather than structurally stabilizing the IMM, MOTS-c translocates from the mitochondria to the cytosol and nucleus. Laboratory studies indicate that MOTS-c primarily targets the AMP-activated protein kinase (AMPK) pathway, influencing cellular glucose uptake, folate metabolism, and gene expression.
| Mechanistic Target | SS-31 (Elamipretide) | MOTS-c |
|---|---|---|
| Primary Target | Cardiolipin (Structural) | AMPK Pathway (Metabolic) |
| Cellular Location | Inner Mitochondrial Membrane | Intracellular / Nuclear translocation |
| Receptor Dependency | Receptor-independent (electrostatic binding) | Receptor-mediated signaling cascades |
Preclinical Research Focus Areas
Experimental applications for these peptides diverge based on their respective mechanisms. Preclinical assays evaluating the SS-31 peptide heavily focus on ischemia-reperfusion models, cellular senescence, and acute oxidative stress environments where rapid preservation of electron transport chain efficiency is necessary. Researchers investigating these structural stabilization properties frequently examine literature via PubMed searches for elamipretide and ischemia-reperfusion.
Conversely, MOTS-c is predominantly utilized in in-vitro models evaluating metabolic homeostasis. Research frequently isolates MOTS-c to observe cellular responses to nutrient deprivation, insulin signaling cascades, and metabolic stress, reflecting its functional role as an endogenous metabolic regulator.
| Research Application Focus | SS-31 (Elamipretide) | MOTS-c |
|---|---|---|
| Primary Preclinical Models | Ischemia-reperfusion, oxidative stress assays | Metabolic dysfunction, glucose regulation models |
| Targeted Cellular Outcome | Preservation of ATP synthesis, ROS reduction | Activation of metabolic enzymes, gene transcription |
| Experimental Timeline Response | Rapid structural stabilization | Downstream metabolic signaling alterations |
Evaluating SS-31 in Preclinical Models of Ischemia-Reperfusion
Preclinical investigations of the SS-31 peptide in ischemia-reperfusion (IR) models focus on its capacity to mitigate mitochondrial permeability transition pore (mPTP) opening and subsequent cellular apoptosis. Laboratory assays utilize simulated ischemia-reperfusion (sIR) protocols in isolated cardiomyocytes and renal tubular epithelial cells to quantify structural preservation, measuring specific biomarkers of mitochondrial swelling and ATP depletion.
Methodological Frameworks for In-Vitro Ischemia-Reperfusion Assays
To replicate the pathological cascade of IR injury in a controlled laboratory environment, researchers frequently subject cultured cell lines to oxygen-glucose deprivation followed by reoxygenation (OGD/R). During the deprivation phase, cellular culture media is replaced with glucose-free buffers inside a hypoxic chamber. The reoxygenation phase introduces standard culture media and normoxia, triggering a rapid, destructive influx of reactive oxygen species (ROS). Evaluating the SS-31 peptide in these models typically involves introducing the compound prior to the hypoxic phase or strictly at the onset of reoxygenation to isolate its mechanisms against reperfusion-induced oxidative stress.
| In-Vitro IR Model | Ischemia Simulation | Reperfusion Simulation | Primary Application of SS-31 |
|---|---|---|---|
| OGD/R (Cellular) | Hypoxic chamber (1% O2), glucose-free media | Normoxic incubator (21% O2), standard glucose media | Pre-incubation or concurrent with reoxygenation |
| Chemical Hypoxia | Addition of Cobalt Chloride (CoCl2) or Antimycin A | Washout of chemical agent, media replacement | Concurrent administration with chemical stressor |
| Isolated Mitochondria | Anoxic buffer suspension, calcium overload | Oxygenated buffer introduction | Direct titration into isolated mitochondrial suspension |
Quantifying Mitochondrial Swelling and Cytochrome C Release
A central focus of SS-31 preclinical research is its interaction with the inner mitochondrial membrane to prevent structural collapse during reperfusion. Ischemia induces calcium overload, which, upon reoxygenation, triggers mPTP opening. This pore formation causes rapid osmotic swelling of the organelle and the eventual rupture of the outer mitochondrial membrane. Researchers quantify this swelling in vitro using isolated mitochondrial fractions and measuring light scattering absorbance at 540 nm (A540). Additionally, the physical dissociation of cytochrome C from cardiolipin is evaluated. Western blot analysis of cytosolic fractions isolates the concentration of cytochrome C released from the mitochondria, providing a direct metric of membrane integrity following peptide exposure.
| Biomarker / Assay Target | Analytical Methodology | Pathological Indicator |
|---|---|---|
| Mitochondrial Swelling | Spectrophotometry (A540 absorbance decrease) | mPTP opening and osmotic dysregulation |
| Cytochrome C Translocation | Subcellular fractionation and Western Blotting | Outer mitochondrial membrane rupture |
| mPTP Activation | Calcein-AM with CoCl2 quenching | Loss of inner membrane impermeability |
Assessing ATP Depletion and Superoxide Generation
The failure to recover intracellular adenosine triphosphate (ATP) following reperfusion indicates irreversible damage to the electron transport chain (ETC). In evaluating the SS-31 peptide, researchers utilize bioluminescence assays to track real-time ATP recovery kinetics during the reoxygenation phase. Because SS-31 binds directly to cardiolipin to optimize electron transfer, experimental models measure the reduction in electron leak. This is quantified by tracking mitochondrial superoxide production utilizing highly specific fluorescent probes. For comprehensive literature on these specific methodological approaches, researchers can query PubMed for related peer-reviewed assay protocols.
| Metabolic Marker | Analytical Reagent / Probe | Cellular Function Measured |
|---|---|---|
| Intracellular ATP | Luciferin-Luciferase Bioluminescence Assay | ETC efficiency and oxidative phosphorylation recovery |
| Mitochondrial Superoxide | MitoSOX Red Fluorescent Probe | Complex I and III electron leak during reoxygenation |
| Membrane Potential (ΔΨm) | JC-1 or TMRE Fluorescent Dyes | Proton motive force maintenance across the inner membrane |
Elamipretide in Clinical Trials: Research Context
Elamipretide (SS-31) occupies a highly specific translational research niche focusing on its capacity to stabilize cardiolipin within the inner mitochondrial membrane. Clinical and preclinical investigations predominantly evaluate the peptide against rare genetic mitochondrial disorders, most notably Barth syndrome and primary mitochondrial myopathy. The investigational framework bridges cellular models of mitochondrial dysfunction with clinical trial data analyzing oxidative stress markers and electron transport chain efficiency.
Translating SS-31 from in-vitro models to clinical evaluation relies on its distinct mechanism of action. Barth syndrome results from mutations in the TAZ (tafazzin) gene, which dictates cardiolipin remodeling. This genetic defect produces abnormal cardiolipin structures, defective mitochondrial cristae architecture, and compromised ATP synthesis. Researchers evaluate elamipretide in these specific models because its structural affinity for cardiolipin theoretically bypasses the enzymatic defect by directly stabilizing the remaining lipid structures. Similarly, in primary mitochondrial myopathy (PMM)—a category encompassing diverse oxidative phosphorylation defects—trial endpoints measure changes in cellular bioenergetics, mitochondrial respiration rates, and downstream systemic markers of oxidative stress.
Current Literature Volume and Database Records
The regulatory and translational interest in elamipretide is reflected in the steady accumulation of peer-reviewed literature and registered study protocols. Investigators frequently monitor major databases to track the progression of SS-31 from isolated cellular assays to multi-phase clinical evaluations. The following table provides a snapshot of the current literature volume using verified search query counts.
| Search Query | PubMed Records | ClinicalTrials.gov Records |
|---|---|---|
| elamipretide | 356 | 21 |
| SS-31 peptide | 362 | 1 |
Mechanistic Rationale in Primary Disease Models
Understanding the clinical research context requires mapping the peptide’s biochemical actions to the specific pathologies observed in mitochondrial diseases. Regulatory frameworks often prioritize these rare conditions for orphan drug investigation to accelerate the collection of safety and efficacy data.
| Investigational Target | Pathological Mechanism | SS-31 Mechanistic Hypothesis |
|---|---|---|
| Barth Syndrome | TAZ gene mutation causing defective cardiolipin acyl-chain remodeling and mitochondrial deformation. | Direct electrostatic binding to aberrant cardiolipin, stabilizing cristae and preventing cytochrome c detachment. |
| Primary Mitochondrial Myopathy (PMM) | Genetic defects in oxidative phosphorylation (OXPHOS) complexes leading to ATP deficiency. | Enhancement of electron transport chain supercomplex assembly and reduction of electron leak across the membrane. |
Translational Biomarkers in SS-31 Evaluation
To quantify the efficacy of elamipretide in both laboratory and clinical settings, researchers utilize a specific set of bioenergetic markers. These metrics allow investigators to correlate in-vitro mitochondrial stabilization with systemic metabolic responses observed in trial subjects.
| Biomarker / Assay | Cellular Function Evaluated | Research Context |
|---|---|---|
| O2 Consumption Rate (OCR) | Electron transport chain efficiency and maximal respiratory capacity. | In-vitro cellular flux analysis of isolated mitochondria. |
| Cytochrome c Retention | Inner mitochondrial membrane permeability and structural integrity. | Apoptosis assays and ischemia-reperfusion models. |
| Reactive Oxygen Species (ROS) | Oxidative stress, electron leak, and lipid peroxidation limits. | Fluorescence-based cellular assays evaluating mitochondrial stress. |
Solid-Phase Peptide Synthesis (SPPS) of SS-31
The synthesis of the SS-31 peptide requires specialized Fmoc solid-phase peptide synthesis (SPPS) protocols to accommodate its alternating aromatic-cationic motif and unnatural structural residues. Utilizing a Rink amide resin to yield the necessary C-terminal amidation, chemists must optimize coupling conditions specifically for D-arginine and the sterically hindered 2,6-dimethyltyrosine (Dmt). Achieving research-grade analytical purity necessitates stringent preparative reverse-phase high-performance liquid chromatography (RP-HPLC) paired with tandem mass spectrometry to isolate the target tetrapeptide from truncated byproducts.
Overcoming Steric Hindrance with Dmt and D-Arginine Incorporation
The primary challenge in manufacturing research-grade SS-31 peptide lies in the sequence itself: D-Arg-Dmt-Lys-Phe-NH2. The incorporation of 2,6-dimethyltyrosine presents significant steric hindrance during the coupling phase. The two methyl groups positioned on the phenolic ring restrict the spatial accessibility of the alpha-amino group. Standard coupling reagents, such as DIC/HOBt, often result in incomplete amide bond formation at this step. To drive the reaction to completion, laboratories typically utilize highly reactive uronium salts like HATU alongside the organic base DIPEA.
Additionally, the N-terminal D-arginine residue, which confers resistance to proteolytic degradation in cellular assays, requires careful monitoring to prevent epimerization during standard Fmoc deprotection cycles using 20% piperidine. Precise temperature control and abbreviated deprotection times maintain the structural integrity of the D-enantiomer.
| Residue Position | Fmoc-Protected Derivative | Synthesis Challenge / Structural Role |
|---|---|---|
| Position 1 (N-terminus) | Fmoc-D-Arg(Pbf)-OH | Requires epimerization control; Pbf protecting group removal demands high TFA concentrations. |
| Position 2 | Fmoc-Dmt-OH | High steric hindrance from 2,6-dimethylation requires aggressive HATU/DIPEA coupling. |
| Position 3 | Fmoc-Lys(Boc)-OH | Straightforward coupling; provides the essential secondary cationic charge for cardiolipin targeting. |
| Position 4 (C-terminus) | Fmoc-Phe-OH | Coupled directly to a Rink amide resin to generate the C-terminal primary amide. |
Resin Cleavage and Deprotection Protocols
Following sequence assembly, the peptide undergoes simultaneous cleavage from the solid support and global side-chain deprotection. The bulky Pbf group protecting the D-arginine guanidino side chain is notoriously difficult to remove, requiring an aggressive trifluoroacetic acid (TFA) cocktail. Scavengers are introduced to prevent the highly reactive carbocations generated during deprotection from re-attaching to the electron-rich Dmt or Phenylalanine rings, an issue frequently reported in the literature regarding aromatic peptide synthesis.
| Cleavage Cocktail Component | Volume Fraction | Chemical Function |
|---|---|---|
| Trifluoroacetic Acid (TFA) | 95% | Cleaves peptide from resin; removes Boc (Lys) and Pbf (Arg) protecting groups. |
| Triisopropylsilane (TIPS) | 2.5% | Acts as a carbocation scavenger to protect aromatic side chains from alkylation. |
| Ultrapure Water (H2O) | 2.5% | Quenches reactive intermediate species generated during Pbf removal. |
Reverse-Phase HPLC Purification and Analytical Validation
The crude cleavage product contains truncated sequences, unreacted scavengers, and deletion peptides. Preparative RP-HPLC using robust C18 stationary phases is mandatory to isolate the pure SS-31 tetrapeptide. The mobile phase traditionally consists of a linear gradient of water and acetonitrile, both modified with 0.1% TFA. The TFA acts as an ion-pairing agent, binding to the highly basic cationic side chains of D-arginine and lysine, thereby improving peak resolution and retention time on the hydrophobic column.
| Analytical Validation Method | Target Parameter | Research-Grade Acceptance Criteria |
|---|---|---|
| Analytical RP-HPLC | Chromatographic Purity | >98.0% principal peak area at 214 nm and 254 nm UV detection. |
| Electrospray Ionization Mass Spectrometry (ESI-MS) | Molecular Weight Confirmation | Observed [M+H]+ matches theoretical mass (639.8 g/mol) within ±0.5 Da. |
| Karl Fischer Titration | Moisture Content | <5.0% residual water by weight in the lyophilized powder. |
Chemical Stability, Storage, and Reconstitution Protocols
The SS-31 peptide (elamipretide) requires strict environmental controls to maintain structural integrity, necessitating the storage of lyophilized powder at -20°C or lower in heavily desiccated conditions. Reconstitution for in-vitro assays demands sterile, pH-buffered solvents to prevent rapid degradation, while the resulting solutions must be immediately aliquoted to mitigate aggregation driven by the compound’s highly cationic nature. Researchers must adhere to precise handling protocols to ensure reproducibility in mitochondrial targeting assays.
Environmental Parameters for Lyophilized Preservation
In its lyophilized state, the alternating aromatic-cationic sequence (D-Arg-Dmt-Lys-Phe-NH2) of the SS-31 peptide is highly hygroscopic. Exposure to ambient humidity induces rapid moisture absorption, which can catalyze hydrolysis at the peptide bonds. Laboratory protocols reported in the literature dictate that the solid-phase powder must remain in a sealed, desiccated container. While short-term transit at ambient temperatures generally maintains molecular stability, long-term preservation requires deep-freeze conditions.
| Storage State | Optimal Temperature | Estimated Stability Window | Environmental Requirement |
|---|---|---|---|
| Lyophilized Powder | -20°C to -80°C | 24 to 36 months | Vacuum sealed, active desiccant |
| Lyophilized Powder | 4°C (Refrigerated) | 30 to 60 days | Dark, low humidity container |
| Lyophilized Powder | 20°C (Ambient) | 14 to 21 days | Sealed away from direct UV light |
Reconstitution Solvents and Aqueous Degradation Kinetics
Transitioning SS-31 from a stable lyophilized powder to an aqueous solution introduces variables that accelerate degradation. The mechanism of action for elamipretide relies on its positive charge interacting with negatively charged cardiolipin on the inner mitochondrial membrane. In solution, this same charge profile can lead to electrostatic interactions with unpassivated glass or low-quality plastic laboratory ware. Reconstitution typically utilizes sterile bacteriostatic water or phosphate-buffered saline (PBS) adjusted to a physiological pH (7.2–7.4). Acidic or highly basic solvents can permanently denature the spatial orientation required for the Szeto-Schiller motif to function in cellular models.
| Reconstitution Solvent | Suitability for SS-31 | Primary Laboratory Application |
|---|---|---|
| Sterile Bacteriostatic Water | Optimal | General in-vitro assays, long-term aliquot freezing |
| Phosphate-Buffered Saline (PBS) | High | Live-cell microscopy, mitochondrial respiration assays |
| Deionized (DI) Water | Suboptimal | Prone to pH fluctuations affecting peptide ionization |
Mitigating Aggregation and Freeze-Thaw Degradation in Aliquots
Once reconstituted, the aqueous stability of the SS-31 peptide drops significantly. The amphiphilic nature of the molecule—possessing both hydrophobic aromatic rings and hydrophilic cationic residues—predisposes it to self-aggregation in prolonged aqueous states. To mitigate this, researchers standardly divide the reconstituted peptide into single-use microcentrifuge aliquots. Repeated freeze-thaw cycles physically shear the peptide chains and nucleate aggregation, rendering the compound inert for in-vitro mitochondrial membrane stabilization assays as established in preclinical models.
| Aqueous State Handling | Temperature | Stability Limit | Degradation Risk |
|---|---|---|---|
| Reconstituted Aliquot (Frozen) | -20°C | Up to 3 months | Minimal, assuming zero freeze-thaw cycles |
| Reconstituted Solution (Liquid) | 4°C | 14 to 21 days | Moderate risk of self-aggregation and oxidation |
| Freeze-Thaw Cycles | Fluctuating | 0 to 1 cycles | High risk of structural shearing and precipitation |
Frequently Asked Questions About SS-31 (elamipretide)
What is the precise amino acid sequence of the SS-31 peptide?
The SS-31 peptide is a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2. It incorporates D-arginine and the unnatural amino acid 2,6-dimethyltyrosine (Dmt) to enhance proteolytic stability.
How does SS-31 differ from traditional cell-penetrating peptides?
Unlike traditional peptides that target cell-surface receptors or utilize endosomal pathways, SS-31 possesses an aromatic-cationic motif that allows it to freely cross cellular membranes. It specifically accumulates in the inner mitochondrial membrane by binding directly to cardiolipin.
What is the relationship between SS-31 and elamipretide?
SS-31 and elamipretide refer to the exact same molecular compound. SS-31 is the original laboratory and research designation, while elamipretide is the assigned United States Adopted Name (USAN) and International Nonproprietary Name (INN).
Does mitochondrial uptake of SS-31 rely on membrane potential?
No, the accumulation of SS-31 within the mitochondria is independent of the mitochondrial membrane potential. This differentiates it from other mitochondria-targeted compounds, such as those utilizing triphenylphosphonium cations, which require active potential gradients.
Why is cardiolipin the primary molecular target for SS-31?
Cardiolipin is a unique, cone-shaped phospholipid localized almost exclusively in the inner mitochondrial membrane. It is essential for maintaining the structural curvature of cristae and anchoring the protein complexes of the electron transport chain.
What are the structural effects of SS-31 binding to cardiolipin?
Preclinical models demonstrate that the SS-31 and cardiolipin interaction inhibits the conversion of cytochrome c into a peroxidase. This structural stabilization helps maintain standard cristae architecture during periods of severe cellular oxidative stress.
How is the SS-31 peptide evaluated against MOTS-c in mitochondrial research?
While both are studied as mitochondrial peptides, MOTS-c is a 16-amino acid mitochondrial-derived peptide that regulates metabolic pathways via AMPK. In contrast, SS-31 is a synthetic tetrapeptide that acts structurally at the membrane level to optimize electron transport.
What are the standard storage conditions for research-grade SS-31?
Lyophilized SS-31 peptide should be stored at -20 degrees Celsius in a tightly sealed, desiccated container protected from light. Once reconstituted in sterile laboratory buffers, aliquots should be utilized promptly or frozen to limit degradation.
Has SS-31 been investigated in models of neurodegeneration?
Yes, researchers have investigated SS-31 in various in-vitro and animal models of neurodegeneration. Literature reports indicate that its small molecular weight and specific physicochemical properties allow it to cross the blood-brain barrier in preclinical assays.